Christopher Nicholas

Christopher R. Nicholas is a clinical researcher focused on the psychopharmacology and clinical application of classical psychedelics and empathogens. His work spans phase I human pharmacokinetic and dose-escalation studies of oral psilocybin in healthy volunteers, experimental investigations of subjective experience and memory (including studies of psilocybin co-administered with midazolam), and collaborative involvement in randomized, double-blind, placebo-controlled phase III trials of MDMA-assisted therapy for severe PTSD.

Nicholas's contributions bridge early-phase safety and pharmacokinetic characterisation with pragmatic therapeutic research and trial methodology. He has contributed to studies examining dose–response subjective effects in healthy volunteers, explored how sedative co-administration alters psychedelic phenomenology and memory encoding, and been involved in developing the conceptual therapeutic framework used in large-scale MDMA-assisted therapy trials. His portfolio reflects an emphasis on rigorous clinical trial design, careful assessment of subjective and cognitive outcomes, and translational approaches that connect psychopharmacology to psychotherapeutic practice in trauma- and mood-related disorders.